查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1797886

分子診斷市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Molecular Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 132 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球分子診斷市場價值為 270 億美元，預計到 2034 年將以 4.2% 的複合年成長率成長，達到 404 億美元。這一穩定成長受到多種因素的推動，例如傳染病病例的增加、分子診斷技術的不斷創新、早期疾病檢測意識的增強、對即時診斷 (POC) 的需求激增以及全球老年人口的快速成長。

分子診斷市場 - IMG1

分子診斷透過分析基因組和蛋白質組（包括DNA、RNA和蛋白質）中的生物標記物，成為識別和監測疾病的重要技術。隨著醫療保健系統面臨提供更快、更準確的診斷解決方案的壓力，該技術在現代臨床實踐中發揮日益重要的作用。賽默飛世爾科技、豪洛捷、希森美康、丹納赫和凱傑等市場主要參與者正在不斷擴展其產品線，以滿足不斷變化的全球醫療需求。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 270億美元
預測值 404億美元
複合年成長率 4.2%

分子診斷涉及高度靈敏和準確的檢測，對於識別包括遺傳性疾病、癌症和傳染病在內的多種疾病至關重要。這種精準度正推動其在已開發市場和新興市場的廣泛應用。在眾多技術中，聚合酶鍊式反應 (PCR) 在 2024 年佔據 70.4% 的市場佔有率，領先市場。 PCR 能夠精確擴增 RNA 和 DNA，並且能夠檢測出即使是微量的遺傳物質，使其成為早期檢測的重要工具，尤其適用於傳染病篩檢和基因檢測。

2024年，腫瘤檢測市場規模達21億美元，預計2034年將達32億美元。全球癌症發生率的上升，以及對早期診斷的需求不斷成長，推動先進分子檢測工具在腫瘤學領域的應用。醫療保健系統正在投資基於分子的儀器、試劑盒和試劑，以實現高靈敏度和特異性，從而改善患者預後並推進癌症管理方案。

2024年，美國分子診斷市場規模達104億美元。由於傳染病發病率持續上升，以及政府大力支持下一代診斷技術的開發和商業化，美國和加拿大市場正呈現強勁成長動能。即使監管標準嚴格，創新​​診斷儀器和試劑盒的推出也受到顯著鼓勵。技術進步和先進分子檢測平台的廣泛應用，正在進一步推動北美市場的發展。

全球分子診斷市場的領先公司包括羅氏公司、Qiagen、安捷倫科技、Biocartis、賽默飛世爾科技、西門子醫療、雅培實驗室、QuidelOrtho Corporation、Bio-Rad Laboratories、Illumina、Becton、Dickinson and Company、Sysmex Corporation、Huwel Lifesciences、Biomerie Houxic、丹納赫集團和丹納赫集團和丹納赫集團和丹納赫集團和丹納赫集團和丹納赫集團。為了鞏固其在競爭激烈的分子診斷領域的地位，各公司正在積極尋求策略聯盟、合併和收購。他們也專注於投資研發，以創新高通量、自動化和多重測試平台。擴大產品組合、獲得監管部門批准和進入新的區域市場正在幫助參與者擴大其全球影響力。此外，人工智慧和數位平台的整合正在提高診斷的準確性和速度，從而提供技術優勢。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
    • 供應商格局
    • 每個階段的增值
    • 影響價值鏈的因素
  • 產業衝擊力
    • 成長動力
      • 全球技術進步和對早期疾病診斷認知的提高
      • POC診斷需求不斷成長
      • 老年人口基數不斷增加
      • 研發計劃數量不斷增加
      • 傳染病發生率上升
    • 產業陷阱與挑戰
      • 分子診斷測試成本高昂
      • 缺乏熟練的人員
    • 市場機會
      • 新興市場的擴張
      • 與人工智慧（AI）的融合
  • 成長潛力分析
  • 技術和創新格局
    • 當前的技術趨勢
    • 新興技術
  • 監管格局
  • 未來市場趨勢
  • 定價分析
  • 差距分析
  • 波特的分析
  • PESTEL分析

第4章：競爭格局

  • 介紹
  • 公司市佔率分析
    • 按地區
      • 北美洲
      • 歐洲
      • 亞太地區
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 關鍵進展
    • 併購
    • 夥伴關係和合作
    • 新產品發布
    • 擴張計劃

第5章：市場估計與預測：依產品類型，2021 - 2034 年

  • 主要趨勢
  • 儀器
  • 試劑和試劑盒

第6章：市場估計與預測：按技術，2021 - 2034 年

  • 主要趨勢
  • 聚合酶鍊式反應（PCR）
  • 雜交
  • 定序
  • 等溫核酸擴增技術（INAAT）
  • 微陣列
  • 其他技術

第7章：市場估計與預測：按應用，2021 - 2034 年

  • 主要趨勢
  • 傳染病診斷
    • 新冠肺炎
    • 流感
    • 呼吸道合胞病毒（RSV）
    • 結核
    • CT/NG
    • 愛滋病
    • C型肝炎
    • B型肝炎
    • 其他傳染病診斷
  • 遺傳疾病檢測
  • 腫瘤學檢測
  • 其他應用

第8章：市場估計與預測：依最終用途，2021 - 2034 年

  • 主要趨勢
  • 醫院和診所
  • 診斷實驗室
  • 其他最終用途

第9章：市場估計與預測：按地區，2021 - 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：公司簡介

  • Abbott Laboratories
  • Agilent Technologies
  • Becton, Dickinson, and Company
  • Biocartis
  • Biomerieux
  • Bio-Rad Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche
  • Hologic
  • Huwel Lifesciences
  • Illumina
  • Qiagen
  • QuidelOrtho Corporation
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific
簡介目錄
Product Code: 434

The Global Molecular Diagnostics Market was valued at USD 27 billion in 2024 and is estimated to grow at a CAGR of 4.2% to reach USD 40.4 billion by 2034. This steady growth is being fueled by multiple converging factors such as rising cases of infectious diseases, continuous innovation in molecular diagnostic technologies, growing awareness of early disease detection, the surging need for point-of-care (POC) diagnostics, and the rapid expansion of the global elderly population.

Molecular Diagnostics Market - IMG1

Molecular diagnostics serves as a vital technique in identifying and monitoring diseases by analyzing biological markers in the genome and proteome, including DNA, RNA, and proteins. With healthcare systems under pressure to deliver faster and more accurate diagnostic solutions, this technique is playing an increasingly central role in modern clinical practice. Major players in the market-such as Thermo Fisher Scientific, Hologic, Sysmex Corporation, Danaher Corporation, and Qiagen-continue to expand their offerings to meet evolving global health needs.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$27 Billion
Forecast Value$40.4 Billion
CAGR4.2%

Molecular diagnostics involves highly sensitive and accurate tests that are critical for identifying a wide array of conditions, including genetic disorders, cancers, and infectious diseases. This accuracy is driving its adoption across both developed and emerging markets. Among the technologies used, polymerase chain reaction (PCR) led the market in 2024 with a 70.4% share. Its precise amplification of RNA and DNA and ability to detect even the smallest quantities of genetic material make PCR an essential tool for early detection, especially for infectious disease screening and genetic testing.

The oncology testing segment was valued at USD 2.1 billion in 2024 and is projected to reach USD 3.2 billion by 2034. Increasing cancer incidence across the globe, along with a rising demand for early diagnosis, is driving the uptake of advanced molecular testing tools in oncology. Healthcare systems are investing in molecular-based instruments, kits, and reagents that enable high sensitivity and specificity, improving patient outcomes and advancing cancer management protocols.

United States Molecular Diagnostics Market generated 10.4 billion in 2024. The U.S. and Canadian markets are witnessing significant momentum due to the continued rise of infectious diseases and strong support for the development and commercialization of next-generation diagnostic technologies. Even with strict regulatory standards in place, there is notable encouragement for the rollout of innovative diagnostic instruments and kits. Technological advancement and widespread adoption of sophisticated molecular testing platforms are helping to drive the market further in North America.

Leading companies operating in the Global Molecular Diagnostics Market include F. Hoffmann-La Roche, Qiagen, Agilent Technologies, Biocartis, Thermo Fisher Scientific, Siemens Healthineers, Abbott Laboratories, QuidelOrtho Corporation, Bio-Rad Laboratories, Illumina, Becton, Dickinson and Company, Sysmex Corporation, Huwel Lifesciences, Biomerieux, Danaher Corporation, and Hologic. To solidify their positions in the competitive molecular diagnostics space, companies are actively pursuing strategic alliances, mergers, and acquisitions. They are also focused on investing in R&D to innovate high-throughput, automated, and multiplex testing platforms. Expanding product portfolios, obtaining regulatory approvals, and entering new regional markets are helping players scale their global footprint. Additionally, integration of AI and digital platforms is enhancing diagnostic accuracy and speed, providing a technological edge.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/Country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Product type
    • 2.2.2 Technology
    • 2.2.3 Application
    • 2.2.4 End use
    • 2.2.5 Regional
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Value addition at each stage
    • 3.1.3 Factor affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Technological advances and increasing awareness towards early disease diagnosis globally
      • 3.2.1.2 Escalating demand for POC diagnostics
      • 3.2.1.3 Increasing geriatric population base
      • 3.2.1.4 Increasing number of R&D initiatives
      • 3.2.1.5 Rising incidences of infectious diseases
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of molecular diagnostic tests
      • 3.2.2.2 Lack of skilled personnel
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion in emerging markets
      • 3.2.3.2 Integration with artificial intelligence (AI)
  • 3.3 Growth potential analysis
  • 3.4 Technology and innovation landscape
    • 3.4.1 Current technological trends
    • 3.4.2 Emerging technologies
  • 3.5 Regulatory landscape
    • 3.5.1 North America
    • 3.5.2 Europe
    • 3.5.3 Asia Pacific
    • 3.5.4 Latin America
    • 3.5.5 Middle East and Africa
  • 3.6 Future market trends
  • 3.7 Pricing analysis
  • 3.8 Gap analysis
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 By region
      • 4.2.1.1 North America
      • 4.2.1.2 Europe
      • 4.2.1.3 Asia Pacific
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Mergers and acquisitions
    • 4.6.2 Partnerships and collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Instruments
  • 5.3 Reagents and kits

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Polymerase chain reaction (PCR)
  • 6.3 Hybridization
  • 6.4 Sequencing
  • 6.5 Isothermal nucleic acid amplification technology (INAAT)
  • 6.6 Microarrays
  • 6.7 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Infectious disease diagnostics
    • 7.2.1 COVID-19
    • 7.2.2 Flu
    • 7.2.3 Respiratory syncytial virus (RSV)
    • 7.2.4 Tuberculosis
    • 7.2.5 CT/NG
    • 7.2.6 HIV
    • 7.2.7 Hepatitis C
    • 7.2.8 Hepatitis B
    • 7.2.9 Other infectious disease diagnostics
  • 7.3 Genetic disease testing
  • 7.4 Oncology testing
  • 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinics
  • 8.3 Diagnostic laboratories
  • 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 Agilent Technologies
  • 10.3 Becton, Dickinson, and Company
  • 10.4 Biocartis
  • 10.5 Biomerieux
  • 10.6 Bio-Rad Laboratories
  • 10.7 Danaher Corporation
  • 10.8 F. Hoffmann-La Roche
  • 10.9 Hologic
  • 10.10 Huwel Lifesciences
  • 10.11 Illumina
  • 10.12 Qiagen
  • 10.13 QuidelOrtho Corporation
  • 10.14 Siemens Healthineers
  • 10.15 Sysmex Corporation
  • 10.16 Thermo Fisher Scientific